Trial register facet
Trial records in obesity and overweight in adults — page 3
208 records bearing on obesity and overweight in adults.
Showing 0 records on this page
Records
208 documents · page 3 of 9
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SUMMIT-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2024 | Very low |
| SURVO-PH2-OBESITY-ADHERENCEprogramme record | Survodutide | Phase 2 | Reported | Observational | — | 2024 | Very low |
| PETRE-PH1B-ELDERLYprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| REIMAGINE-1-DDIprogramme record | Amycretin | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| SUMMIT-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-4-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| PETRE-PH1B-PKprogramme record | Petrelintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| STEP-HFpEF | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 529 | 2023 | Moderate |
| SELECT | Semaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 17,604 | 2023 | High |
| OASIS-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 667 | 2023 | Moderate |
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| SURMOUNT-3 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 806 | 2023 | High |
| RETA-PH2-OBESITY | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 338 | 2023 | Moderate |
| ORFO-PH2-OBESITY | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 272 | 2023 | Moderate |
| CAGRI-SEMA-PH2-T2D | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, active-controlled | 92 | 2023 | Low |
| MAZ-PH2-OBESITY | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 248 | 2023 | Moderate |
| DANU-PH2B-OBESITY | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 605 | 2023 | Not rated |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SELECT-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2023 | Very low |
| OASIS-1-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2023 | Very low |
| RETA-PH2-OBESITY-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
page 3 of 9